ALG 010093
Alternative Names: ALG-010093Latest Information Update: 28 Dec 2023
Price :
$50 *
At a glance
- Originator Aligos Therapeutics
- Class Antivirals; Oligonucleotides
- Mechanism of Action Hepatitis B virus X protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatitis B
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for preclinical development in Hepatitis-B in USA
- 08 Nov 2019 Updated Pharmacodynamics data from preclinical studies in Hepatitis B presented at the 70th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2019)
- 08 Nov 2019 Preclinical trials in Hepatitis B in USA (unspecified route)